Conor F. Larkin

His midstream and downstream oil and gas work includes representation of master limited partnerships and negotiating major infrastructure projects and joint ventures, as well as long-term storage, terminalling, and throughput agreements. His life sciences work includes structuring and negotiating royalty monetization transactions on behalf of investors and royalty holders.

Before attending law school, Conor worked in the corporate advisory division of Thomson Reuters in New York, where he counseled Fortune 500 companies on their investor relations efforts and best practices for investor relations and financial communications.

Significant transactional representations (in addition to general day-to-day corporate and securities compliance representations) include:

Life Sciences and Royalty Monetization Transactions

• Ligand Pharmaceuticals in its royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical study of D-Fi, Castle Creek’s lead candidate, in patients with dystrophic epidermolysis bullosa
• Ligand Pharmaceuticals in its purchase of third-party and synthetic royalty interests from Agenus Inc. to support Agenus’s ongoing botensilimab and balstilimab clinical development program
• Integra LifeSciences Holdings Corporation in its acquisition from Johnson & Johnson of Acclarent Inc.,  a medical device company supporting ear, nose, and throat (ENT) surgeons delivering minimally invasive technologies
• Integra LifeSciences Holdings Corporation in the sale of its Extremity Orthopedics business to Smith+Nephew
• Healthcare Royalty Partners in numerous royalty monetization transactions, including acquisitions of royalty and revenue interests from inventors, universities and companies including Infinity Pharmaceuticals Inc., Acorda Therapeutics Inc., Albireo Pharma Inc., REGENXBIO Inc., Clearside Biomedical Inc., Rhythm Pharmaceuticals Inc., and Cara Therapeutics Inc.
• Antares Pharma in its $960 million sale to Halozyme
• Nevakar Inc. in royalty monetization transactions with NovaQuest Capital Management and H.I.G. Capital
• Phathom Pharmaceuticals Inc. in a revenue interest financing for up to $260 million in non-dilutive capital with Sagard Healthcare Partners, NovaQuest Capital Management, and Hercules Capital Inc.
• Medical device tubing manufacturer Fluortek in its sale to Nordson Corporation
• Aptevo Therapeutics in two royalty monetization transactions
• Formula Pharmaceuticals in its merger with CoImmune

Energy Transactions

• MPLX LP in the strategic combination of the Whistler Pipeline, a joint venture of MPLX, WhiteWater Midstream, and I Squared, with Enbridge Inc.’s Rio Bravo Pipeline project, in which Enbridge contributed the Rio Bravo Pipeline and $350 million in cash in exchange for an ownership stake in the newly formed joint venture, and which valued the existing Whistler Pipeline and its subsidiaries at $4.9 billion
• Fomento Económico Mexicano, S.A.B. de C.V. (FEMSA), a Mexican multinational beverage and retail company, in its $350 million acquisition from Delek US Holdings of approximately 250 retail gas stations and convenience stores across New Mexico, Texas, and Arkansas
• Buckeye Partners in its sale of South Texas Gateway Terminal, which is jointly owned with affiliates of Marathon Petroleum and Phillips 66 and is the second largest crude export facility in North America and operates out of a deep-water marine terminal in Ingleside, Texas, to Gibson Energy Inc. for $1.1 billion
• HF Sinclair Corporation (f/k/a HollyFrontier Corporation) in its $1.8 billion acquisition on Sinclair Oil
• Buckeye Partners in its acquisition of Magellan’s independent terminals network comprised of 26 refined petroleum products terminals with approximately 6 million barrels of storage located primarily in the southeastern United States for $435 million
• HollyFrontier in its $350 million acquisition of the Puget Sound refinery from Shell
• HollyFrontier Corp. in the $655 million acquisition of Sonneborn US Holdings Inc. and Sonneborn Coöperatief U.A., producers of high purity specialty products as one of the world’s largest dedicated suppliers of white oils, petrolatums and waxes.
• MPLX Delaware Basin NGL LLC, a subsidiary of MPLX LP (MPLX) and Marathon Petroleum Corp. (MPC), in a joint venture with WhiteWater Midstream LLC to acquire a 30% interest in a 323-mile natural gas liquids pipeline in Texas from EPIC Midstream LLC
• MPLX LP in a joint venture with WhiteWater Midstream, West Texas Gas, and Cheniere Energy regarding the construction, ownership, and operation of a 21.5 mile, 42-inch natural gas pipeline to be known as the ADCC Pipeline
• Buckeye Partners, L.P. in the formation of a joint venture with Phillips 66 Partners LP and Andeavor to develop a new $300 million deep-water, open access marine terminal in Ingleside, Texas.
• HollFrontier Corp. in its $1.25 billion IDR elimination transaction with Holly Energy Partners, including the acquisition of common units of Holly Energy Partners.
• HollyFrontier Corp. in its $845 million acquisition of Suncor Energy’s Petro-Canada lubricants business.
• Representation of a terminalling and storage company in its $850 million acquisition of 20 liquids storage marine terminals, including the negotiation of long-term storage and throughput agreements.
• Representation of master limited partnership in its acquisition of a propane distribution business.